NeurAxis, Inc. logo

NeurAxis, Inc. (NRXS)

Market Open
26 Oct, 06:34 PM
AMEX AMEX
$
7. 33
-0.07
-0.9459%
$
95.44M Market Cap
- P/E Ratio
- Div Yield
70,951 Volume
0 Eps
$ 7.4
Previous Close
Investors:
Add Transaction
Day Range
7.31 7.45
Year Range
2.21 9.33
Want to track NRXS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NRXS trading today lower at $7.33, a decrease of -0.9459% from yesterday's close, completing a monthly decrease of -0.8119% or -$0.06. Over the past 12 months, NRXS stock gained 65.8371%.
NRXS is not paying dividends to its shareholders.
The last earnings report, released on Apr 14, 2026, exceeded the consensus estimates by 0.24%. On average, the company has surpassed earnings expectations by 0.09%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

NRXS Chart

People also search for

Lineage Cell Therapeutics, Inc.
$ 0.98
-2.16%
Perspective Therapeutics Inc.
$ 1.27
-20.8075%
Electromed, Inc.
$ 26.57
+0.7774%
PLX
Protalix BioTherapeutics, Inc.
$ 2.5
-2.1569%
Armata Pharmaceuticals, Inc.
$ 3.48
-4.533%
Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.

Zacks | 1 month ago
NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

Seekingalpha | 1 month ago
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.

Zacks | 2 months ago

NeurAxis, Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
JRS
James RG Skjong Ulland Investment Advisors LLC
1,000 $2,420 $7,635 $5,215 215.5%
Irene Chou
Irene Chou Panoramic Capital LLC
115,000 $593,600 $848,700 $255,100 42.98%
Hui Fai Tam
Hui Fai Tam Caitong International Asset Management Co. Ltd.
14 $102 $103.46 $1.46 1.43%

NeurAxis, Inc. (NRXS) FAQ

What is the stock price today?

The current price is $7.33.

On which exchange is it traded?

NeurAxis, Inc. is listed on AMEX.

What is its stock symbol?

The ticker symbol is NRXS.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 95.44M.

Has NeurAxis, Inc. ever had a stock split?

No, there has never been a stock split.

NeurAxis, Inc. Profile

Biotechnology Industry
Healthcare Sector
Brian Carrico CEO
AMEX Exchange
64134X201 CUSIP
US Country
24 Employees
- Last Dividend
- Last Split
9 Aug 2023 IPO Date

Overview

NeurAxis, Inc. is a pioneering medical technology enterprise focused on the innovation of neuromodulation therapies. These therapies are devised to alleviate chronic and debilitating conditions affecting both children and adults throughout the United States. Initially known as Innovative Health Solutions, Inc., the company underwent a name change to NeurAxis, Inc. in March 2022. Founded in 2011 and headquartered in Carmel, Indiana, NeurAxis, Inc. is at the forefront of offering groundbreaking solutions, significantly enhancing patient care. The company primarily caters to healthcare providers, including hospitals and clinics, distributing its technological advancements widely across the healthcare sector.

Products and Services

Listed below are the products and services offered by NeurAxis, Inc.:

  • IB-Stim:

This is a cutting-edge percutaneous electrical nerve field stimulation system. It's specifically designed for use in younger patients, ranging from 11 to 18 years of age, who suffer from functional abdominal pain associated with irritable bowel syndrome (IBS). The system operates by delivering targeted electrical nerve field stimulation, providing a non-pharmacological treatment option that aims to significantly reduce the symptoms of IBS in this age group. By focusing on such a niche, NeurAxis, Inc. contributes to fulfilling a critical gap in pediatric healthcare solutions.

Contact Information

Address: 11550 North Meridian Street
Phone: (812) 689-0791